837 the Adjustable Continence Therapy (Act©) System: Preliminary Results of the North America Act Clinical Study Group

Carmel, Maude; Tu, Le-Mai; Aboseif, Sherif R.; Nash, Steven; Baum, Neil; Galloway, Niall T.M.; Pommerville, Peter; Bresette, John F.; Whitmore, K. E.; Sluteky, J.

doi:10.1016/s1569-9056(07)60832-x

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The overall success rate in our series was 59%, which in our opinion is acceptable given the diverse characteristics of the study population. Carmel et al [9] reported on the preliminary results of the North America ACT FDA study group in which 79 women with recurrent stress UI were enrolled. The average urine loss based on the 24-hour pad test decreased from 46 g at baseline to 12 g at 12 months.…”

Section: Discussionmentioning

confidence: 99%

Adjustable Continence Therapy for Female Urinary Incontinence: A Minimally Invasive Option for Difficult Cases

Wachter

Henning²,

Roehlich³

et al. 2008

Urol Int

View full text Add to dashboard Cite

Aim: To assess the role of Adjustable Continence Therapy® (ACT) as a minimally invasive treatment for women with urinary incontinence (UI) after failed previous incontinence surgery or when conventional surgical treatment was considered problematic. Material and Methods: The ACT device consists of two balloons implanted at the level of the bladder neck using a paraurethral/vaginal approach with the aim of coapting the urethra. Balloon filling can be adjusted postoperatively via a port placed in the labia majora. Results: 41 women with a mean age of 73 (range 42–93) years were evaluated. 15 (38%) women had failed previous UI surgery with 83% having undergone prior pelvic surgery. Mean follow-up was 25 (5–60) months. Adjustment of the ACT balloons was necessary in 28 women (69%). Overall, 44% of women became fully continent, 15% reported a significant improvement of UI, a further 29% had a slight improvement, while 12% indicated no change. ACT-related complications occurred in 16 (39%) patients, including balloon migration, transient urinary obstruction and balloon leakage. Conclusions: ACT is an attractive minimally invasive option for women with UI with previous failed incontinence surgery or when conventional incontinence surgery carries a high risk of failure.

show abstract

Section: Discussionmentioning

confidence: 99%

Adjustable Continence Therapy for Female Urinary Incontinence: A Minimally Invasive Option for Difficult Cases

Wachter

Henning²,

Roehlich³

et al. 2008

Urol Int

View full text Add to dashboard Cite

show abstract

Minimally Invasive Therapies for Female Stress Urinary Incontinence: the Current Status of Bioinjectables/New Devices (Adjustable Continence Therapy, Urethral Submucosal Collagen Denaturation by Radiofrequency)

Crivellaro¹,

Smith²

2009

The Scientific World JOURNAL

View full text Add to dashboard Cite

The aim of this review is to provide an update on the current status of evolving minimally invasive therapies for stress urinary incontinence. Bioinjectables have been available for some time and their current status is reviewed. The adjustable continence device has been used as a salvage procedure for females for a number of years in clinical trials, yet many are unfamiliar with it. Lastly, radiofrequency via a transurethral route has also been utilized in small numbers and will be updated. These later two emerging technologies need further exposure to better define their role in our clinical practice.

show abstract

837 the Adjustable Continence Therapy (Act©) System: Preliminary Results of the North America Act Clinical Study Group

Cited by 2 publications

References 0 publications

Adjustable Continence Therapy for Female Urinary Incontinence: A Minimally Invasive Option for Difficult Cases

Adjustable Continence Therapy for Female Urinary Incontinence: A Minimally Invasive Option for Difficult Cases

Minimally Invasive Therapies for Female Stress Urinary Incontinence: the Current Status of Bioinjectables/New Devices (Adjustable Continence Therapy, Urethral Submucosal Collagen Denaturation by Radiofrequency)

Contact Info

Product

Resources

About